nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

01.06.2015 | Original Paper

Decreased quinolinic acid in the hippocampus of depressive patients: evidence for local anti-inflammatory and neuroprotective responses?

verfasst von: Mandy Busse, Stefan Busse, Aye Mu Myint, Tomasz Gos, Henrik Dobrowolny, Ulf J. Müller, Bernhard Bogerts, Hans-Gert Bernstein, Johann Steiner

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Disturbances of glutamatergic neurotransmission and mononuclear phagocyte system activation have been described uni- and bipolar depression (UD/BD). Linking the glutamate and immune hypotheses of depression, quinolinic acid (QUIN) is synthesized by activated microglia and acts as an endogenous N-methyl-D-aspartate glutamate receptor (NMDA-R) agonist with neurotoxic properties. Recently, we observed an increased microglial QUIN expression in the subgenual and supracallosal, but not in the pregenual part of the anterior cingulate cortex in postmortem brains of suicide cases with severe depression. Since several hints point to a role of the hippocampus in depression, we extended our study and addressed the question whether microglial QUIN is also changed in subregions of the hippocampus (CA1 and CA2/3 areas) in these patients. Postmortem brains of 12 acutely depressed patients (UD, n = 6; BD, n = 6) and 10 neuropsychiatric healthy age- and gender-matched control subjects were analyzed using QUIN-immunohistochemistry. Hippocampal volumes were determined in order to assess possible neurotoxic or neurodegenerative aspects. Microglial QUIN expression in the whole group of depressed patients was either comparable (left CA1, right CA2/3) or decreased (right CA1: p = 0.004, left CA2/3: p = 0.044) relative to controls. Post hoc tests showed that QUIN was reduced both in UD and BD in the right CA1 field (UD, p = 0.048; BD, p = 0.031). No loss of hippocampal volume was detected. Our data indicate that UD and BD are associated with a local reduction in QUIN-immunoreactive microglia in the hippocampus and underline the importance of the NMDA-R signaling in depressive disorders.

Nur mit Berechtigung zugänglich

Steiner J, Bogerts B, Sarnyai Z, Walter M, Gos T, Bernstein HG, Myint AM (2012) Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: potential role of glial NMDA receptor modulators and impaired blood–brain barrier integrity. World J Biol Psychiatry 13(7):482–492CrossRefPubMed

Milne A, MacQueen GM, Yucel K, Soreni N, Hall GB (2009) Hippocampal metabolic abnormalities at first onset and with recurrent episodes of a major depressive disorder: a proton magnetic resonance spectroscopy study. Neuroimage 47(1):36–41CrossRefPubMed

Block W, Traber F, von Widdern O, Metten M, Schild H, Maier W, Zobel A, Jessen F (2009) Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response. Int J Neuropsychopharmacol 12(3):222–415

Drexhage RC, Knijff EM, Padmos RC, Heul-Nieuwenhuijzen L, Beumer W, Versnel MA, Drexhage HA (2010) The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 10(1):59–76CrossRefPubMed

Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, McCorkle R, Seligman DA, Schmidt K (2001) The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 15(3):199–226CrossRefPubMed

Padmos RC, Hillegers MH, Knijff EM, Vonk R, Bouvy A, Staal FJ, de Ridder D, Kupka RW, Nolen WA, Drexhage HA (2008) A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry 65(4):395–407CrossRefPubMed

Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H (1996) Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatr Scand 94(3):198–204CrossRefPubMed

Maes M, Van der Planken M, Stevens WJ, Peeters D, DeClerck LS, Bridts CH, Schotte C, Cosyns P (1992) Leukocytosis, monocytosis and neutrophilia: hallmarks of severe depression. J Psychiatr Res 26(2):125–134CrossRefPubMed

Myint AM, Kim YK (2003) Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses 61(5–6):519–525CrossRefPubMed

10.

Myint AM, Kim YK (2014) Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 48:304–313CrossRefPubMed

11.

Guillemin GJ, Smith DG, Smythe GA, Armati PJ, Brew BJ (2003) Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv Exp Med Biol 527:105–112CrossRefPubMed

12.

Guillemin GJ, Smythe G, Takikawa O, Brew BJ (2005) Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49(1):15–23CrossRefPubMed

13.

Stone TW, Behan WM, MacDonald M, Darlington LG (2000) Possible mediation of quinolinic acid-induced hippocampal damage by reactive oxygen species. Amino Acids 19(1):275–281CrossRefPubMed

14.

Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, Mawrin C, Brisch R, Bielau H, Meyer zu Schwabedissen L, Bogerts B, Myint AM (2011) Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation 8(94):1–9

15.

Horn DI, Yu C, Steiner J, Buchmann J, Kaufmann J, Osoba A, Eckert U, Zierhut KC, Schiltz K, He H, Biswal B, Bogerts B, Walter M (2010) Glutamatergic and resting-state functional connectivity correlates of severity in major depression—the role of pregenual anterior cingulate cortex and anterior insula. Front Syst Neurosci 4(33):10

16.

Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F (2000) Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 47(4):305–313CrossRefPubMed

17.

Rosenberg DR, Macmaster FP, Mirza Y, Smith JM, Easter PC, Banerjee SP, Bhandari R, Boyd C, Lynch M, Rose M, Ivey J, Villafuerte RA, Moore GJ, Renshaw P (2005) Reduced anterior cingulate glutamate in pediatric major depression: a magnetic resonance spectroscopy study. Biol Psychiatry 58(9):700–704CrossRefPubMed

18.

Maes M, Verkerk R, Vandoolaeghe E, Lin A, Scharpe S (1998) Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 97(4):302–308CrossRefPubMed

19.

Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH (1982) Increased serum glutamate in depressed patients. Archiv fur Psychiatrie und Nervenkrankheiten 232(4):299–304CrossRefPubMed

20.

Levine J, Panchalingam K, Rapoport A, Gershon S, McClure RJ, Pettegrew JW (2000) Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 47(7):586–593CrossRefPubMed

21.

Curzon G, Bridges PK (1970) Tryptophan metabolism in depression. J Neurol Neurosurg Psychiatry 33(5):698–704CrossRefPubMedCentralPubMed

22.

Yüksel C, Ongur D (2010) Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry 68(9):785–794CrossRefPubMedCentralPubMed

23.

Schwarcz R, Kohler C (1983) Differential vulnerability of central neurons of the rat to quinolinic acid. Neurosci Lett 38(1):85–90CrossRefPubMed

24.

MacQueen G, Frodl T (2011) The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research? Mol Psychiatry 16(3):252–264CrossRefPubMed

25.

Collingridge GL, Volianskis A, Bannister N, France G, Hanna L, Mercier M, Tidball P, Fang G, Irvine MW, Costa BM, Monaghan DT, Bortolotto ZA, Molnar E, Lodge D, Jane DE (2013) The NMDA receptor as a target for cognitive enhancement. Neuropharmacology 64:13–26CrossRefPubMed

26.

Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C (1999) Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry 174:297–303CrossRefPubMed

27.

Rey MJ, Schulz P, Costa C, Dick P, Tissot R (1989) Guidelines for the dosage of neuroleptics. I: chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacol 4(2):95–104CrossRefPubMed

28.

Perry PJ, Alexander B (1986) Sedative/hypnotic dependence: patient stabilization, tolerance testing, and withdrawal. Drug Intell Clin Pharm 20(7–8):532–537PubMed

29.

Gos T, Myint AM, Schiltz K, Meyer-Lotz G, Dobrowolny H, Busse S, Müller UJ, Mawrin C, Bernstein HG, Bogerts B, Steiner J (2014) Reduced microglial immunoreactivity for endogenous NMDA receptor agonist quinolinic acid in the hippocampus of schizophrenia patients. Brain Behav Immun (in press)

30.

Ellison-Wright I, Glahn DC, Laird AR, Thelen SM, Bullmore E (2008) The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. Am J Psychiatry 165(8):1015–1023CrossRefPubMedCentralPubMed

31.

Hsu SM, Soban E (1982) Color modification of diaminobenzidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry. J Histochem Cytochem 30(10):1079–1082CrossRefPubMed

32.

Polak M, Haymaker W, Johnson JE, D´Amelio F (1982) Neuroglia and their reactions. In: Haymaker W, Adams RD (eds) Histology and histopathology of the nervous system. Charles C Thomas Publishing, Springfield, pp 363–480

33.

Erhardt S, Lim CK, Linderholm KR, Janelidze S, Lindqvist D, Samuelsson M, Lundberg K, Postolache TT, Traskman-Bendz L, Guillemin GJ, Brundin L (2013) Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 38(5):743–752CrossRefPubMedCentralPubMed

34.

Stone TW, Behan WM (2007) Interleukin-1beta but not tumor necrosis factor-alpha potentiates neuronal damage by quinolinic acid: protection by an adenosine A2A receptor antagonist. J Neurosci Res 85(5):1077–1085CrossRefPubMed

35.

Platenik J, Stopka P, Vejrazka M, Stipek S (2001) Quinolinic acid-iron (ii) complexes: slow autoxidation, but enhanced hydroxyl radical production in the fenton reaction. Free Radical Res 34(5):445–459CrossRef

36.

Ngai LY, Herbert J (2005) Glucocorticoid enhances the neurotoxic actions of quinolinic acid in the striatum in a cell-specific manner. J Neuroendocrinol 17(7):424–434CrossRefPubMed

37.

Maes M, Mihaylova I, Ruyter MD, Kubera M, Bosmans E (2007) The immune effects of trycats (tryptophan catabolites along the IDO pathway): relevance for depression—and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol Lett 28(6):826–831PubMed

38.

Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, Leonard B (2007) Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 98(1–2):143–151CrossRefPubMed

39.

Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, Spivey JR, Saito K, Miller AH (2010) CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 15(4):393–403CrossRefPubMedCentralPubMed

40.

Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9(1):46–56CrossRefPubMedCentralPubMed

41.

Kaestner F, Hettich M, Peters M, Sibrowski W, Hetzel G, Ponath G, Arolt V, Cassens U, Rothermundt M (2005) Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. J Affect Disord 87(2–3):305–311CrossRefPubMed

42.

Miller AH, Maletic V, Raison CL (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65(9):732–741CrossRefPubMedCentralPubMed

43.

Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, Bernstein HG, Bogerts B (2008) Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 42(2):151–157CrossRefPubMed

44.

Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS (2000) Hippocampal volume reduction in major depression. Am J Psychiatry 157(1):115–118CrossRefPubMed

45.

Sheline YI (1996) Hippocampal atrophy in major depression: a result of depression-induced neurotoxicity? Mol Psychiatry 1(4):298–299PubMed

46.

Frodl T, Meisenzahl EM, Zetzsche T, Born C, Groll C, Jager M, Leinsinger G, Bottlender R, Hahn K, Moller HJ (2002) Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry 159(7):1112–1118CrossRefPubMed

47.

Ashtari M, Greenwald BS, Kramer-Ginsberg E, Hu J, Wu H, Patel M, Aupperle P, Pollack S (1999) Hippocampal/amygdala volumes in geriatric depression. Psychol Med 29(3):629–638CrossRefPubMed

48.

Axelson DA, Doraiswamy PM, McDonald WM, Boyko OB, Tupler LA, Patterson LJ, Nemeroff CB, Ellinwood EH Jr, Krishnan KR (1993) Hypercortisolemia and hippocampal changes in depression. Psychiatry Res 47(2):163–173CrossRefPubMed

49.

Coffey CE, Wilkinson WE, Weiner RD, Parashos IA, Djang WT, Webb MC, Figiel GS, Spritzer CE (1993) Quantitative cerebral anatomy in depression. A controlled magnetic resonance imaging study. Arch Gen Psychiatry 50(1):7–16CrossRefPubMed

50.

Pantel J, Schroder J, Essig M, Popp D, Dech H, Knopp MV, Schad LR, Eysenbach K, Backenstrass M, Friedlinger M (1997) Quantitative magnetic resonance imaging in geriatric depression and primary degenerative dementia. J Affect Disord 42(1):69–83CrossRefPubMed

51.

Rusch BD, Abercrombie HC, Oakes TR, Schaefer SM, Davidson RJ (2001) Hippocampal morphometry in depressed patients and control subjects: relations to anxiety symptoms. Biol Psychiatry 50(12):960–964CrossRefPubMed

52.

Vakili K, Pillay SS, Lafer B, Fava M, Renshaw PF, Bonello-Cintron CM, Yurgelun-Todd DA (2000) Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study. Biol Psychiatry 47(12):1087–1090CrossRefPubMed

53.

Monkul ES, Hatch JP, Nicoletti MA, Spence S, Brambilla P, Lacerda AL, Sassi RB, Mallinger AG, Keshavan MS, Soares JC (2007) Fronto-limbic brain structures in suicidal and non-suicidal female patients with major depressive disorder. Mol Psychiatry 12(4):360–366CrossRefPubMed

54.

Kemmerer M, Nasrallah HA, Sharma S, Olson SC, Martin R, Lynn MB (1994) Increased hippocampal volume in bipolar disorder. Biol Psychiatry 35(9):626CrossRef

55.

Swayze VW II, Andreasen NC, Alliger RJ, Yuh WT, Ehrhardt JC (1992) Subcortical and temporal structures in affective disorder and schizophrenia: a magnetic resonance imaging study. Biol Psychiatry 31(3):221–240CrossRefPubMed

56.

Hauser P, Altshuler LL, Berrettini W, Dauphinais ID, Gelernter J, Post RM (1989) Temporal lobe measurement in primary affective disorder by magnetic resonance imaging. J Neuropsychiatry Clin Neurosci 1(2):128–134CrossRefPubMed

57.

Hsieh MH, McQuoid DR, Levy RM, Payne ME, MacFall JR, Steffens DC (2002) Hippocampal volume and antidepressant response in geriatric depression. Int J Geriatr Psychiatry 17(6):519–525CrossRefPubMed

58.

Mervaala E, Fohr J, Kononen M, Valkonen-Korhonen M, Vainio P, Partanen K, Partanen J, Tiihonen J, Viinamaki H, Karjalainen AK, Lehtonen J (2000) Quantitative MRI of the hippocampus and amygdala in severe depression. Psychol Med 30(1):117–125CrossRefPubMed

59.

Shah PJ, Ebmeier KP, Glabus MF, Goodwin GM (1998) Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br J Psychiatry 172:527–532CrossRefPubMed

60.

Steffens DC, Byrum CE, McQuoid DR, Greenberg DL, Payne ME, Blitchington TF, MacFall JR, Krishnan KR (2000) Hippocampal volume in geriatric depression. Biol Psychiatry 48(4):301–309CrossRefPubMed

61.

MacQueen GM, Campbell S, McEwen BS, Macdonald K, Amano S, Joffe RT, Nahmias C, Young LT (2003) Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci USA 100(3):1387–1392CrossRefPubMedCentralPubMed

62.

Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F, Nitsch R, Bechmann I (2005) Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. Faseb J 19(10):1347–1349PubMed

63.

Sanacora G, Treccani G, Popoli M (2012) Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 62(1):63–77CrossRefPubMedCentralPubMed

64.

65.

Braidy N, Guillemin GJ, Mansour H, Chan-Ling T, Grant R (2011) Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female wistar rats. FEBS J 278(22):4425–4434CrossRefPubMed

Titel: Decreased quinolinic acid in the hippocampus of depressive patients: evidence for local anti-inflammatory and neuroprotective responses?
verfasst von: Mandy Busse
Stefan Busse
Aye Mu Myint
Tomasz Gos
Henrik Dobrowolny
Ulf J. Müller
Bernhard Bogerts
Hans-Gert Bernstein
Johann Steiner
Publikationsdatum: 01.06.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 4/2015
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-014-0562-0

Neu im Fachgebiet Psychiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

Disturbed cortico–amygdalar functional connectivity as pathophysiological correlate of working memory deficits in bipolar affective disorder

Repeated dose titration versus age-based method in electroconvulsive therapy: a pilot study

Retinal dysfunction of contrast processing in major depression also apparent in cortical activity

Body fat distribution and associations with metabolic and clinical characteristics in bipolar individuals